Cipla gains on the BSE
Cipla is currently trading at Rs. 1325.00, up by 3.25 points or 0.25% from its previous closing of Rs. 1321.75 on the BSE.
The scrip opened at Rs. 1311.95 and has touched a high and low of Rs. 1325.00 and Rs. 1292.80 respectively. So far 38176 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1672.20 on 23-Oct-2025 and a 52 week low of Rs. 1283.00 on 27-Jan-2026.
Last one week high and low of the scrip stood at Rs. 1354.15 and Rs. 1292.80 respectively. The current market cap of the company is Rs. 106954.20 crore.
The promoters holding in the company stood at 29.21%, while Institutions and Non-Institutions held 54.64% and 16.14% respectively.
Cipla’s wholly owned subsidiary -- Cipla USA, Inc is recalling over 400 cartons of generic anti-cancer medication, Nilotinib Capsules, due to a manufacturing issue. Cipla USA, Inc has recalled Nilotinib Capsules in two strengths (150 mg and 200 mg).
On February 18, 2026, Cipla USA, Inc had initiated the Class III voluntary recall. A Class III recall is initiated in a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
